Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018

CAMBRIDGE, Mass., March 14, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that preliminary data from its Phase 1 clinical trial evaluating BLU-667 for the treatment of RET-altered non-small cell lung cancer, medullary thyroid cancer, and other advanced solid tumors will be presented in an oral presentation in a Clinical Trials Plenary Session at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, April 14-18, 2018.

Presentation Title: Highly potent and selective RET inhibitor, BLU-667, achieves proof-of-concept in a Phase I study of advanced, RET-altered solid tumors
Session Title: Advances in Precision Cancer Medicine
Session Date & Time: Sunday, April 15, 2018 from 3:00 – 5:00 p.m. CT (4:00 – 6:00 p.m. ET)
Abstract Number: 9226
Location: N Hall C - McCormick Place North (Level 1)

Investor Event and Webcast Information

Blueprint Medicines will host an investor event on Sunday, April 15, 2018 beginning at 7:30 p.m. CT (8:30 p.m. ET) in Chicago to review the preliminary clinical data presented at AACR for BLU-667. The event will be webcast live and can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.blueprintmedicines.com. A replay of the webcast will be available approximately two hours after the event and will be available for 30 days following the event.

About Blueprint Medicines

Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing multiple programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

SOURCE Blueprint Medicines Corporation